Ferguson Wellman Capital Management Inc. Lowers Stake in Pfizer Inc. (NYSE:PFE)

Ferguson Wellman Capital Management Inc. lessened its position in Pfizer Inc. (NYSE:PFEGet Rating) by 30.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 651,834 shares of the biopharmaceutical company’s stock after selling 285,248 shares during the period. Pfizer makes up 1.3% of Ferguson Wellman Capital Management Inc.’s investment portfolio, making the stock its 21st largest holding. Ferguson Wellman Capital Management Inc.’s holdings in Pfizer were worth $34,176,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of Pfizer during the fourth quarter worth about $3,351,891,000. Capital International Investors grew its holdings in Pfizer by 3,059.6% in the first quarter. Capital International Investors now owns 38,530,003 shares of the biopharmaceutical company’s stock valued at $1,994,698,000 after purchasing an additional 37,310,556 shares during the period. Vanguard Group Inc. lifted its position in Pfizer by 3.0% during the first quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock valued at $24,801,210,000 after buying an additional 13,790,348 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of Pfizer by 577.8% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock worth $715,270,000 after purchasing an additional 10,440,786 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Pfizer by 28.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 43,391,119 shares of the biopharmaceutical company’s stock worth $2,246,359,000 after purchasing an additional 9,537,621 shares in the last quarter. Institutional investors and hedge funds own 67.90% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $44.57 on Friday. The firm has a market capitalization of $250.14 billion, a price-to-earnings ratio of 8.72, a P/E/G ratio of 0.54 and a beta of 0.70. Pfizer Inc. has a 52-week low of $40.94 and a 52-week high of $61.71. The stock has a fifty day moving average of $48.40 and a 200 day moving average of $50.33. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42.

Pfizer (NYSE:PFEGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.95 by $0.09. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The firm had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. During the same quarter in the previous year, the company posted $1.07 earnings per share. The company’s revenue was up 46.8% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 6.54 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s dividend payout ratio (DPR) is 31.31%.

Wall Street Analyst Weigh In

Several analysts have weighed in on PFE shares. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research note on Tuesday, June 28th. Barclays set a $50.00 target price on Pfizer in a report on Thursday, September 1st. Berenberg Bank set a $44.00 price objective on Pfizer in a report on Wednesday, September 14th. Morgan Stanley lowered their price target on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a report on Friday, July 8th. Finally, SVB Leerink lowered their price target on Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a report on Friday, July 29th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.00.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.